NovoCure Balance Sheet Health
Financial Health criteria checks 4/6
NovoCure has a total shareholder equity of $359.4M and total debt of $569.7M, which brings its debt-to-equity ratio to 158.5%. Its total assets and total liabilities are $1.1B and $762.1M respectively.
Key information
158.5%
Debt to equity ratio
US$569.65m
Debt
Interest coverage ratio | n/a |
Cash | US$870.15m |
Equity | US$359.36m |
Total liabilities | US$762.07m |
Total assets | US$1.12b |
Recent financial health updates
No updates
Recent updates
Financial Position Analysis
Short Term Liabilities: 038's short term assets ($1.0B) exceed its short term liabilities ($160.2M).
Long Term Liabilities: 038's short term assets ($1.0B) exceed its long term liabilities ($601.8M).
Debt to Equity History and Analysis
Debt Level: 038 has more cash than its total debt.
Reducing Debt: 038's debt to equity ratio has increased from 118.1% to 158.5% over the past 5 years.
Balance Sheet
Cash Runway Analysis
For companies that have on average been loss-making in the past, we assess whether they have at least 1 year of cash runway.
Stable Cash Runway: 038 has sufficient cash runway for more than 3 years based on its current free cash flow.
Forecast Cash Runway: Insufficient data to determine if 038 has enough cash runway if its free cash flow continues to grow or shrink based on historical rates.